蟾酥注射液治疗鲍曼不动杆菌重症肺炎的临床疗效  

Clinical Efficacy of Chansu Injection in the Treatment of Severe Pneumonia Caused by AcinetobacterBaumannii

作　　者：王海娟 刘青 陈文星[2] WANG Hai-Juan;LIU Qing;CHENWen-Xing(Department of Respiratory,Hebei Eighth People's Hospital,Shjiazhuang 050013,China;School of pharmacy,Nanjing University of traditional Chinese medicine,Nanjing 210023,China)

机构地区：[1]河北省第八人民医院呼吸科,石家庄050013 [2]南京中医药大学药学院,南京210023

出　　处：《中国药物经济学》2023年第5期65-68,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨蟾酥注射液治疗鲍曼不动杆菌引起的重症肺炎的临床疗效。方法选取2020年10月至2021年10月河北省第八人民医院收治的60例鲍曼不动杆菌重症肺炎患者作为研究对象,按随机数字表法分为对照组和观察组,各30例。对照组采用西医常规治疗,观察组加用蟾酥注射液进行治疗,两组均治疗7 d。比较两组患者感染指标(白细胞计数、C反应蛋白、降钙素原),临床疗效,预后指标(28d生存率、ICU时间、感染控制窗出现时间),疾病严重程度评分(急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分、序贯器官衰竭(SOFA)评分),不良反应发生情况。结果治疗后,两组白细胞计数、C反应蛋白、降钙素原较治疗前明显降低(P<0.05),且观察组白细胞计数、C反应蛋白、降钙素原明显低于对照组(P<0.05)。观察组治疗有效率高于对照组,差异有统计学意义(P<0.05)。观察组28d生存率明显高于对照组(P<0.05),ICU时间和感染控制窗出现时间较对照组明显缩短(P<0.05)。治疗后,两组APACHEⅡ评分和SOFA评分均较治疗前明显降低(P<0.05),且观察组APACHEⅡ评分和SOFA评分明显低于对照组(P<0.05)。所有患者治疗期间未出现严重不良反应,无死亡病例。结论鲍曼不动杆菌重症肺炎患者在常规西医治疗的基础上联合应用蟾酥注射液治疗,有利于提高临床治疗效果,缩短感染控制窗时间,改善患者预后,且安全性较好。Objective To explore the clinical efficacy of Chansu injection in the treatment of severe pneumonia caused by Acinetobacter baumannii.Methods Sixty patients with severe pneumonia caused by Acinetobacter baumannii admitted to the Eighth People's Hospital of Hebei Province from October 2020 to October 2021 were selected as the study subjects.They were randomly divided into a control group and an observation group,with 30 cases in each group.The control group was treated with conventional Western medicine,while the observation group was treated with Chansu injection.Both groups were treated for 7 days.The infection indicators(white blood cell count,C-reactive protein,Calcitonin),clinical efficacy,prognostic indicators(28 day survival rate,ICU time,time of infection control window),disease severity score(APACHE II score,sequential organ failure(SOFA)score),and adverse reactions of the two groups were compared.Results After treatment,the white blood cell count,C-reactive protein and pro Calcitonin in the two groups were significantly lower than those before treatment(P<0.05),and the white blood cell count,C-reactive protein and pro Calcitonin in the observation group were significantly lower than those in the control group(P<0.05).The effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The 28 day survival rate of the observation group was significantly higher than that of the control group(P<0.05),and the ICU time and infection control window appearance time were significantly shortened compared to the control group(P<0.05).After treatment,the APACHEII and SOFA scores of both groups were significantly reduced compared to before treatment(P<0.05),and the APACHE I and SOFA scores of the observation group were significantly lower than those of the control group(P<0.05).No serious adverse reactions or deaths occurred during the treatment period for all patients.Conclusion Combined treatment of Acinetobacter baumannii patien

关 键 词：蟾酥注射液 重症肺炎 鲍曼不动杆菌 白细胞 降钙素原 

分 类 号：R563.1[医药卫生—呼吸系统] R287[医药卫生—内科学]